• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention.股腘动脉支架内再狭窄的血管造影特征:与血管内介入治疗后长期预后的关系。
Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1168-74. doi: 10.1002/ccd.24983. Epub 2013 Jun 3.
2
Laser Atherectomy for Treatment of Femoropopliteal In-Stent Restenosis.准分子激光血管成形术治疗股腘动脉支架内再狭窄
J Endovasc Ther. 2015 Aug;22(4):506-13. doi: 10.1177/1526602815592133. Epub 2015 Jun 30.
3
Laser atherectomy and drug-coated balloons for the treatment of femoropopliteal in-stent restenosis: 2-Year outcomes.激光动脉粥样切除术和药物涂层球囊治疗股腘段支架内再狭窄:2 年结果。
Catheter Cardiovasc Interv. 2020 Feb 15;95(3):439-446. doi: 10.1002/ccd.28636. Epub 2019 Dec 9.
4
Predictors of recurrence after paclitaxel drug-coated balloon use for treating femoropopliteal in-stent restenosis.紫杉醇药物涂层球囊治疗股腘段支架内再狭窄后复发的预测因素。
Vascular. 2024 Aug;32(4):834-841. doi: 10.1177/17085381231162123. Epub 2023 Mar 10.
5
Classification and clinical impact of restenosis after femoropopliteal stenting.股腘动脉支架置入后再狭窄的分类和临床影响。
J Am Coll Cardiol. 2012 Jan 3;59(1):16-23. doi: 10.1016/j.jacc.2011.09.036.
6
Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.紫杉醇洗脱球囊与标准血管成形术治疗股浅动脉和腘动脉近端支架内再狭窄糖尿病患者以降低再狭窄:DEBATE-ISR研究的三年结果
J Endovasc Ther. 2016 Feb;23(1):52-7. doi: 10.1177/1526602815614555. Epub 2015 Oct 28.
7
Turbo-Power™ Laser Atherectomy Combined with Drug-coated Balloon Angioplasty is Associated with Improved One-Year Outcomes for the Treatment of Tosaka II and III Femoropopliteal In-stent Restenosis.Turbo-Power™ 激光动脉切除术联合药物涂层球囊血管成形术治疗 Tosaka II 和 III 型股腘动脉支架内再狭窄的一年随访结果改善。
Cardiovasc Revasc Med. 2020 Jun;21(6):771-778. doi: 10.1016/j.carrev.2019.10.006. Epub 2019 Oct 18.
8
Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.血管内超声衍生的支架尺寸作为股浅动脉镍钛诺支架植入术后血管造影再狭窄的预测指标
J Endovasc Ther. 2016 Jun;23(3):424-32. doi: 10.1177/1526602816641669. Epub 2016 Apr 4.
9
Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions.血管内超声指导下的血管大小对股腘动脉病变支架植入术后中期结果的影响。
J Endovasc Ther. 2020 Feb;27(1):77-85. doi: 10.1177/1526602819896293.
10
Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.药物洗脱支架植入术治疗股腘动脉支架内闭塞的疗效
J Endovasc Ther. 2016 Jun;23(3):461-7. doi: 10.1177/1526602816639721. Epub 2016 Mar 22.

引用本文的文献

1
Evaluation of Femoropopliteal In-Stent Restenosis Characteristics Stratified by Stent Design.按支架设计分层评估股腘动脉支架内再狭窄特征
J Clin Med. 2023 Nov 22;12(23):7225. doi: 10.3390/jcm12237225.
2
Design of the FP-RESTORE study: a protocol for prospective, observational study of real-world treatments with endovascular therapy in patients with femoropopliteal artery Tosaka III in-stent restenosis.FP-RESTORE 研究设计:一项关于股浅动脉托萨卡 III 型支架内再狭窄患者采用血管内治疗真实世界治疗的前瞻性、观察性研究方案。
BMJ Open. 2022 Dec 6;12(12):e060200. doi: 10.1136/bmjopen-2021-060200.
3
Current developments in endovascular therapy of peripheral vascular disease.外周血管疾病血管内治疗的当前进展
J Thorac Dis. 2020 Apr;12(4):1681-1694. doi: 10.21037/jtd.2019.12.130.
4
Drug-coated balloon in superficial femoral artery in-stent restenosis.药物涂层球囊用于股浅动脉支架内再狭窄
Postepy Kardiol Interwencyjnej. 2018;14(1):9-14. doi: 10.5114/aic.2018.74350. Epub 2018 Mar 22.
5
Intravascular ultrasound guided directional atherectomy versus directional atherectomy guided by angiography for the treatment of femoropopliteal in-stent restenosis.血管内超声引导下定向斑块旋切术与血管造影引导下定向斑块旋切术治疗股腘动脉支架内再狭窄的比较
Ther Adv Cardiovasc Dis. 2018 Jan;12(1):17-22. doi: 10.1177/1753944717745509.
6
The association between periprocedural factors and the late outcome of percutaneous stenting of lower extremity arteries. A retrospective cohort study.围手术期因素与下肢动脉经皮支架置入术后远期疗效的关联。一项回顾性队列研究。
Postepy Kardiol Interwencyjnej. 2015;11(2):108-13. doi: 10.5114/pwki.2015.52283. Epub 2015 Jun 22.

本文引用的文献

1
Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis.药物洗脱球囊治疗股浅动脉支架内再狭窄。
J Am Coll Cardiol. 2012 Oct 30;60(18):1739-42. doi: 10.1016/j.jacc.2012.07.033. Epub 2012 Oct 3.
2
Clinical evaluation of a paclitaxel-eluting balloon for treatment of femoropopliteal arterial disease: 12-month results from a multicenter Italian registry.紫杉醇洗脱球囊治疗股腘动脉疾病的临床评估:多中心意大利注册研究 12 个月结果。
JACC Cardiovasc Interv. 2012 Mar;5(3):331-8. doi: 10.1016/j.jcin.2011.11.010.
3
Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study.准分子激光联合球囊血管成形术和肝素涂层自膨式支架移植物治疗股腘动脉支架内再狭窄:SALVAGE 研究的 12 个月结果。
Catheter Cardiovasc Interv. 2012 Nov 1;80(5):852-9. doi: 10.1002/ccd.23475. Epub 2012 Mar 15.
4
Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial.镍钛诺支架植入术与球囊血管成形术治疗间歇性跛行患者股浅动脉和腘动脉近段病变:RESILIENT 随机试验 3 年随访结果。
J Endovasc Ther. 2012 Feb;19(1):1-9. doi: 10.1583/11-3627.1.
5
Classification and clinical impact of restenosis after femoropopliteal stenting.股腘动脉支架置入后再狭窄的分类和临床影响。
J Am Coll Cardiol. 2012 Jan 3;59(1):16-23. doi: 10.1016/j.jacc.2011.09.036.
6
Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.载紫杉醇聚合物涂层的镍钛合金支架治疗膝上股浅动脉和腘动脉病变:Zilver PTX 单臂临床研究的 12 个月安全性和有效性结果。
J Endovasc Ther. 2011 Oct;18(5):613-23. doi: 10.1583/11-3560.1.
7
Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results.紫杉醇洗脱支架在股腘动脉疾病中优于球囊血管成形术和裸金属支架:Zilver PTX 随机研究 12 个月结果。
Circ Cardiovasc Interv. 2011 Oct 1;4(5):495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324. Epub 2011 Sep 27.
8
Outcomes following treatment of femoropopliteal in-stent restenosis: a single center experience.股腘动脉支架内再狭窄的治疗结果:单中心经验。
Catheter Cardiovasc Interv. 2011 Oct 1;78(4):604-8. doi: 10.1002/ccd.23022. Epub 2011 May 12.
9
Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial.镍钛诺支架植入与球囊血管成形术治疗股浅动脉和腘动脉近段病变:RESILIENT 随机试验 12 个月结果。
Circ Cardiovasc Interv. 2010 Jun 1;3(3):267-76. doi: 10.1161/CIRCINTERVENTIONS.109.903468. Epub 2010 May 18.
10
A qualitative and quantitative angiographic analysis of stent fracture late following sirolimus-eluting stent implantation.西罗莫司洗脱支架植入术后晚期支架断裂的定性和定量血管造影分析
Am J Cardiol. 2009 Apr 1;103(7):923-9. doi: 10.1016/j.amjcard.2008.12.022.

股腘动脉支架内再狭窄的血管造影特征:与血管内介入治疗后长期预后的关系。

Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention.

机构信息

Division of Cardiovascular Medicine and the Vascular Center, University of California, Davis Medical Center, Sacramento, California.

出版信息

Catheter Cardiovasc Interv. 2013 Dec 1;82(7):1168-74. doi: 10.1002/ccd.24983. Epub 2013 Jun 3.

DOI:10.1002/ccd.24983
PMID:23630047
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3836909/
Abstract

OBJECTIVES

The purpose of this study was to identify the relationship between angiographic patterns of restenosis and outcomes after endovascular treatment of femoro-popliteal in-stent restenosis (FP-ISR).

BACKGROUND

ISR is a frequent clinical problem after femoro-popliteal stenting.

METHODS

This was a single center study of all endovascular interventions for FP-ISR from 2006 to 2012. Class I ISR was defined as focal lesions ≤50 mm; Class II ISR as lesions > 50 mm; and Class III ISR as stent chronic total occlusion. Recurrent ISR was defined as peak systolic velocity ratio > 2.4 by duplex ultrasound.

RESULTS

Among 75 cases of FP-ISR, 28 (37%) were Class I, 22 (29%) were Class II, and 25 (33%) were Class III. The mean lesion length was 26 mm for Class I, 135 mm for Class II, and 178 mm for Class III ISR. Patients with Class III ISR more frequently had ISR extending into both the superficial femoral and popliteal artery (48% vs. 18%, P = 0.005). Balloon angioplasty was used most frequently to treat Class I ISR, while adjunctive atherectomy and/or stenting was used for almost all cases of Class III ISR. During 2-year follow-up, rates of repeat restenosis were 39% for Class I, 67% for Class II, and 72% for Class III ISR (P = 0.04). Rates of stent occlusion were 8% for Class I, 11% for Class II, and 52% for Class III ISR (P = 0.009). Class III ISR was associated with significantly increased risk of recurrent ISR (HR 2.4, 95% CI 1.1-5.6) and recurrent occlusion (HR 5.8, 95% CI 1.8-19.0) compared to other types of ISR.

CONCLUSION

Angiographic patterns of FP-ISR are important determinants of subsequent outcomes. Repeat restenosis and occlusion remain common despite currently available technologies.

摘要

目的

本研究旨在确定股腘段支架内再狭窄(FP-ISR)血管造影再狭窄模式与血管内治疗后结局之间的关系。

背景

ISR 是股腘段支架置入后的常见临床问题。

方法

这是一项 2006 年至 2012 年期间对所有 FP-ISR 血管内治疗的单中心研究。I 级 ISR 定义为局限性病变 ≤ 50mm;II 级 ISR 为病变 > 50mm;III 级 ISR 为支架慢性完全闭塞。通过双功能超声检查,再发 ISR 定义为收缩期峰值速度比 > 2.4。

结果

在 75 例 FP-ISR 中,28 例(37%)为 I 级,22 例(29%)为 II 级,25 例(33%)为 III 级。I 级 ISR 的平均病变长度为 26mm,II 级 ISR 为 135mm,III 级 ISR 为 178mm。III 级 ISR 患者的 ISR 更频繁地延伸至股浅动脉和腘动脉(48%比 18%,P = 0.005)。球囊血管成形术最常用于治疗 I 级 ISR,而辅助旋切术和/或支架置入术几乎用于所有 III 级 ISR 病例。在 2 年随访期间,I 级 ISR 的再狭窄率为 39%,II 级 ISR 的再狭窄率为 67%,III 级 ISR 的再狭窄率为 72%(P = 0.04)。I 级 ISR 的支架闭塞率为 8%,II 级 ISR 的支架闭塞率为 11%,III 级 ISR 的支架闭塞率为 52%(P = 0.009)。与其他类型的 ISR 相比,III 级 ISR 与再发 ISR(HR 2.4,95%CI 1.1-5.6)和再发闭塞(HR 5.8,95%CI 1.8-19.0)的风险显著增加相关。

结论

FP-ISR 的血管造影模式是随后结局的重要决定因素。尽管目前有可用的技术,但再发再狭窄和闭塞仍然很常见。